Watch BJDX. Know when insiders buy.
One email the day a filing lands. Free.
BJDX
Bluejay Diagnostics, Inc.
1.03
+0.20 +23.80%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$7.3MNET CASH —52W 0.83 – 14.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.3M | −$2.3M | — | -1.12 | −$1.5M | $143K | −$1.6M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$1.9M | −$1.9M | — | -1.95 | −$1.6M | $19K | −$1.6M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.5M | −$1.4M | — | -10.63 | −$1.5M | — | — | Mar 6 |
| Q3 2025 · Sep 30 | — | — | — | −$1.6M | −$1.6M | — | -1.01 | −$1.4M | — | — | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$2M | −$2M | — | -5.64 | −$2.1M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$1.9M | −$1.9M | — | -13.46 | −$1.2M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.5M | −$1.4M | — | -173.57 | −$1.5M | $1K | −$1.5M | Mar 6 |
| Q3 2024 · Sep 30 | — | — | — | −$1.4M | −$1.5M | — | -76.94 | −$2.2M | $227 | −$2.2M | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$1.9M | −$2.5M | — | -256.16 | −$1.9M | $270K | −$2.2M | Nov 7 |
| Q1 2024 · Mar 31 | — | — | — | −$2.4M | −$2.3M | — | -394.76 | −$2.3M | $35K | −$2.3M | Nov 7 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.4M | −$2.3M | — | -3573.10 | −$2.8M | $88K | −$2.9M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$2.3M | −$2.3M | — | -16.67 | −$1.1M | $74K | −$1.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7M | −$6.8M | — | -15.25 | −$6.1M | $174K | −$6.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$7.2M | −$7.7M | — | -456.75 | −$7.8M | $307K | −$8.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$10.3M | −$10M | — | -3631.48 | −$8.3M | $704K | −$9M | — | — |
| FY2022 · to Dec 31 | $249K | 19.6% | −$9.3M | −$9.3M | -3733.1% | -9.22 | −$7.7M | $1.2M | −$8.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$3.2M | −$3.5M | — | -0.41 | −$4.4M | $24K | −$4.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$1.2M | −$1.2M | — | -0.37 | −$509K | — | — | — | — |
Every number comes from Bluejay Diagnostics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.